Division of Urologic Oncology, Department of Urology, New York University Langone Medical Center, New York, New York, USA.
Curr Opin Urol. 2014 Mar;24(2):155-61. doi: 10.1097/MOU.0000000000000031.
A variety of techniques have emerged for the optimization of prostate biopsy. In this review, we summarize and critically discuss the most recent developments regarding the optimal systematic biopsy and sampling labeling along with multiparametric MRI and magnetic resonance-targeted biopsies.
The use of 10-12-core-extended sampling protocols increases cancer detection rates compared with traditional sextant sampling and reduces the likelihood that patients will require a repeat biopsy, ultimately allowing more accurate risk stratification without increasing the likelihood of detecting insignificant cancers. As the number of cores increases above 12 cores, the increase in diagnostic yield becomes marginal. However, the limitations of this technique include undersampling, oversampling, and the need for repetitive biopsy. MRI and magnetic resonance-targeted biopsies have demonstrated superiority over systematic biopsies for the detection of clinically significant disease and representation of disease burden, while deploying fewer cores and may have applications in men undergoing initial or repeat biopsy and those with low-risk cancer on or considering active surveillance.
A 12-core systematic biopsy that incorporates apical and far-lateral cores in the template distribution allows maximal cancer detection, avoidance of a repeat biopsy while minimizing the detection of insignificant prostate cancers. MRI-guided prostate biopsy has an evolving role in both initial and repeat prostate biopsy strategies, as well as active surveillance, potentially improving sampling efficiency, increasing the detection of clinically significant cancers, and reducing the detection of insignificant cancers.
为了优化前列腺活检,出现了多种技术。在这篇综述中,我们总结并批判性地讨论了最近在系统活检和采样标记、多参数 MRI 和磁共振靶向活检方面的最佳发展。
与传统的六区分样相比,使用 10-12 芯扩展采样方案可提高癌症检出率,并降低患者需要重复活检的可能性,最终可以更准确地进行风险分层,而不会增加检出非显著癌症的可能性。当芯数增加到 12 个以上时,诊断收益的增加变得微不足道。然而,该技术的局限性包括采样不足、过采样和需要重复活检。MRI 和磁共振靶向活检在检测临床显著疾病和疾病负担方面优于系统活检,同时使用的芯数较少,可能适用于初次或重复活检的男性以及接受主动监测的低危癌症患者。
在模板分配中纳入尖部和远外侧芯的 12 芯系统活检可实现最大的癌症检出率,避免重复活检,同时最大限度地减少非显著前列腺癌的检出。MRI 引导的前列腺活检在初始和重复前列腺活检策略以及主动监测中具有不断发展的作用,可能提高采样效率,增加临床显著癌症的检出率,并减少非显著癌症的检出率。